Trial Profile
A Randomised, Double-Blind, Phase III Study to Compare the Efficacy and Safety of Cediranib (AZD2171, RECENTIN) When Added to 5 Fluorouracil, Leucovorin and Oxaliplatin (FOLFOX) or Capecitabine and Oxaliplatin (XELOX) With the Efficacy and Safety of Placebo When Added to FOLFOX or XELOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jun 2019
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms HORIZON-II
- Sponsors AstraZeneca
- 13 Jun 2019 Trial has been completed in UK.
- 08 Dec 2016 This trial was completed in Czech Republic (end date: 2016-08-17), according to European Clinical Trials Database.
- 07 Nov 2016 Status changed from active, no longer recruiting to completed.